“Well, thanks, Travis, for the question. I'll give it a start and then hand it over to Thierry. I mean, look, on the top line, obviously, as you mentioned, we had a really strong quarter with CAS. We still -- we think that growth is going to continue and become a larger part of the company, obviously.”

In context

“ank of America. Travis Steed: First, I'll start on just the comments on accelerating revenue growth next year and growing earnings, high single digits. When you think about CAS obviously -- can you hear me okay? Can you hear me okay? Geoffrey Martha: There we go. Thierry Pieton: Yes. Travis Steed: Okay. I just wanted to ask about the accelerating revenue growth for next year and also the the commitment to grow earnings in high single digits. I guess when you think about the overall portfolio, obviously, CAS is starting to hit tougher comps and this quarter, surgical is only growing 1%. So just trying to think about how you get that business accelerating with Hugo and just like the commitment to be able to deliver on the commitments that you've kind of laid out for FY '27? Geoffrey Martha: Well, thanks, Travis, for the question. I'll give it a start and then hand it over to Thierry. I mean, look, on the top line, obviously, as you mentioned, we had a really strong quarter with CAS. We still -- we think that growth is going to continue and become a larger part of the company, obviously. We're well positioned there. And then we -- our other big growth drivers, particularly Simplicity for hypertension and Altaviva for overactive bladder, we see them beginning to kick in here even in Q4. And then you've got a number of other businesses here that are going to start growing faster than they have been here recently. One is CST with the Stealth AXiS. I'm sure we'll get some questions on that. But I do think this is kind of underappreciated, quite frankly, by the Street. This is not just a new robot. It's not just an extension of [indiscernible], it's a whole new platform that has a lot of benefits to it, and I think that's going to create growth for the short and long term for CST. And then Neurovascular is going to kick up as well. Neurovascular has got a number of new product”